Generic name: abacavir and lamivudine, also called 3TC
Brand names: Kivexa (EU) and Epzicom (US)
Class: Combined NRTI (nukes) tablets
Common (affecting up to 1 in 10 people): Hypersensitivity reaction*, rash, nausea, vomiting, diarrhoea, fever, headache, tiredness, loss of appetite, stomach pain, hair loss, insomnia (difficulty sleeping), general feeling of being unwell, runny nose, cough, joint pain, muscle pain. Uncommon side effects (affecting up to 1 in 100 people): Anaemia (a low red blood cell count), neutropenia (a low white blood cell count), thrombocytopenia (a decrease in the number of cells involved in blood clotting), an increase in liver enzymes. These side effects would show up in blood tests.
Tablet comprises 600mg abacavir and 300mg lamivudine.Take one tablet once a day.
Take with or without food.
*If you are planning to take Kivexa, or any treatment containing abacavir, your doctor should carry out a blood test for a gene called HLA-B*5701. You're more likely to have a hypersensitivity reaction to abacavir if you have this gene. If the test shows that you do have the gene, you should not take Kivexa, or any other treatment containing abacavir.
Last reviewed on 19/12/2016 Next review: 19/12/2019
Any questions? Email firstname.lastname@example.org Information included on this website was correct at the time of publication.
Data and image supplied by NAM.
Various people talk about their experiences of living with HIV.
CAB - Citizens Advice Bureau
HIV Drug Interactions
George House Trust
Equality and Human Rights Commission
Copyright 2017 © Terrence Higgins Trust is a registered charity in England and Wales (reg. no. 288527)
Company reg. no. 1778149 and a registered charity in Scotland (reg. no. SC039986). Registered office: 314-320 Gray's Inn Road, London, WC1X 8DP.